Dermatitis, respiratory drug drives Regeneron-Sanofi collaboration to profitability
The companies also reported a European dermatitis approval and successful topline results from a Phase III study of the drug, Dupixent.
The companies also reported a European dermatitis approval and successful topline results from a Phase III study of the drug, Dupixent.